{"name":"NKMax America","slug":"nkmax","ticker":"Private","exchange":"Private","domain":"nkmaxamerica.com","description":"NKMax America is a private biotechnology company focused on developing innovative cell therapies and immuno-oncology treatments. The company's pipeline includes several promising candidates, with a primary focus on cancer treatment. NKMax America is a relatively small player in the cell therapy and immuno-oncology space, but its research and development efforts have garnered attention from investors and industry experts. The company's top drugs are currently in various stages of clinical development.","hq":"Santa Ana, CA","founded":0,"employees":"","ceo":"Paul Song","sector":"Cell Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"NK-101 patent cliff ($100M at risk)","drug":"NK-101","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"NK-102 patent cliff ($50M at risk)","drug":"NK-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"NKMax America Receives FDA Orphan Drug Designation for NK-101","summary":"The FDA granted orphan drug designation to NKMax America's NK-101 for the treatment of a rare form of blood cancer.","drugName":"NK-101","sentiment":"positive"},{"date":"2023-08-10","type":"deal","headline":"NKMax America Partners with Leading Cancer Research Institute","summary":"NKMax America announced a strategic partnership with a leading cancer research institute to advance its cell therapy pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAxOGhLNy13RXU4TVVtT1VBMWpqRm44MU02TkVyNG1pRWJ4SUFhNjRiQW1JQWczdVo4WlJrLUlpVEUya2lEcFU0ME9FWWowSFlPSmN2N2Z1RTQzaDZkNW9jZVJJWXRfZmJidDlBMmV30gFyQVVfeXFMUHBDbFJjNV82cmpGOEd1NTVtaENYc0M2VWlaZ3VKZkhyYXpCa2YwNHRGUG9GRUllWlJpSnVfOVlQQzhVRko3SXlCNjZXeGIxa2s4T2Fma0l0M0xSbjJhZWN6clNnbm5tb1VSTkVGZ0t6cmZR?oc=5","date":"2023-02-23","type":"regulatory","source":"koreabiomed.com","summary":"NKMAX's NK cell therapy for Parkinson’s scores FDA compassionate use approval - koreabiomed.com","headline":"NKMAX's NK cell therapy for Parkinson’s scores FDA compassionate use approval","sentiment":"positive"}],"patents":[{"drugName":"NK-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":100000000},{"drugName":"NK-102","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Cancer Immunotherapy","Cell Therapy"],"financials":null,"yahoo":null}